Is Arrowhead Pharmaceuticals a Better Buy Than Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals fell -16% during the past Month. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer Arrowhead Pharmaceuticals gives you more. Arrowhead Pharmaceuticals (ARWR) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Alnylam Pharmaceuticals (ALNY) stock, suggesting you may be better off investing in ARWR
- ARWR’s Last 12 Months revenue growth was 23258.2%, vs. ALNY’s 53.2%.
- In addition, its Last 3-Year Average revenue growth came in at 7719.5%, ahead of ALNY’s 51.4%.
- ARWR’s LTM margin is higher: 11.9% vs. ALNY’s 8.2%.
These differences become even clearer when you look at the financials side by side. The table highlights how ALNY’s fundamentals stack up against those of ARWR on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| ALNY | ARWR | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 197.6 | 89.6 | ARWR |
| Revenue Growth | |||
| Last Quarter | 149.3% | � | ARWR |
| Last 12 Months | 53.2% | 23258.2% | ARWR |
| Last 3 Year Average | 51.4% | 7719.5% | ARWR |
| Operating Margins | |||
| Last 12 Months | 8.2% | 11.9% | ARWR |
| Last 3 Year Average | -7.1% | -5666.8% | ALNY |
| Momentum | |||
| Last 3 Year Return | 76.3% | 72.2% | ALNY |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: ALNY Revenue Comparison | ARWR Revenue Comparison
See more margin details: ALNY Operating Income Comparison | ARWR Operating Income Comparison
- Nokia Stock Has More Than Doubled. Here’s What’s Fueling The Rally
- Broadcom’s Hidden Risk: VMware Under Pressure?
- Is eBay Stock A Compounding Engine?
- Amazon Stock’s Simple Path To 20% Upside
- AMD Stock At $230? Get Paid 12% To Wait
- Is HCA Healthcare Stock Utilizing Systematic Share Retirement for Long-Term Alpha?
See detailed fundamentals on Buy or Sell ARWR Stock and Buy or Sell ALNY Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| ALNY Return | 30% | 40% | -19% | 23% | 69% | 1% | 208% | <=== | |
| ARWR Return | -14% | -39% | -25% | -39% | 253% | 2% | -12% | ||
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% | ||
| Monthly Win Rates [3] | |||||||||
| ALNY Win Rate | 50% | 58% | 50% | 33% | 67% | 100% | 60% | ||
| ARWR Win Rate | 50% | 42% | 25% | 42% | 67% | 100% | 54% | ||
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 65% | <=== | ||
| Max Drawdowns [4] | |||||||||
| ALNY Max Drawdown | -2% | -29% | -36% | -25% | -5% | 0% | -16% | ||
| ARWR Max Drawdown | -24% | -58% | -48% | -42% | -47% | 0% | -37% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | 0% | -7% | <=== | |
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 1/5/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read ARWR Dip Buyer Analyses and ALNY Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.
Still not sure about ALNY or ARWR? Consider portfolio approach.
Why Stock Pickers Win More With Multi Asset Portfolios
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices